You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A cost-effective bioreactor to advance functional tissue engineering of cartilage

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: ARCTOS Technology Solutions, LLC            Topic: DLA18A001

    Universal Technology Corporation (UTC) has teamed with the University of Dayton Research Institute (UDRI), Stratonics, and Macy Consulting to demonstrate not only the transitionability into commercial systems, but also to develop the data analytics and monitoring and control requirements to extract the full value fromseveral sensors, including the Stratonics ThermaViz, acoustic and profilometry se ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  3. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices

    SBC: N8 MEDICAL INC            Topic: NHLBI

    ABSTRACT Infection is a serious and potentially fatal complication of surgery to deliver cardiovascular implantable electronic devicesCIEDsi epacemakers and implantable cardioverter defibrillatorsUntreated device related infection is associated with mortality rates as high asCurrentlyonly one antibiotic impregnated mesh has been FDA approved for placement in surgical incisions to reduce infections ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Morphing Moulage for Medical Training (AMM-MT)

    SBC: Vcom3D, Inc.            Topic: DHA17A002

    For this Phase I SBIR proposal, Vcom3D proposes to design advanced medical moulage that accurately simulates the progression of an injury or pathology by morphing through a series of clinical states to enable learners to confirm the progression of the wound and to determine whether iatrogenic errors or pathologies occurred duing treatment. The physical morphing moulage may be applied to medical m ...

    STTR Phase I 2017 Department of DefenseDefense Health Agency
  7. Advancing clemizole for hepatitis C: towards a pre-IND package

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Advancing Formulation of STING agonist for Universal Flu Vaccine

    SBC: IMMvention Therapeutix, Inc.            Topic: NIAID

    Summary Influenza virusa member of the orthomyxovirus familyhas three different types that infect humansABand CTypes A and B produce annual epidemicsand type A influenzawhich resides asymptomatically in birdscan cause pandemic infections in humansIn addition to common flu like symptomse gfeverchillsmalaisemuscle painin susceptible populations influenza can induce potentially fatal secondary compli ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: Engineering Resources Group, Inc            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Allergen???Fc-gamma1 proteins to treat food allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% of young children. It is clearly on the rise. Peanut allergy, which affects around 1% of the population, is among the most severe food allergies, r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government